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Abstract: In the recent years, African swine fever has become the biggest animal health threat to the
swine industry. To facilitate quick genetic analysis of its causative agent, the African swine fever
virus (ASFV), we developed a simple and efficient method for next generation sequencing of the viral
DNA. Execution of the protocol does not demand complicated virus purification steps, enrichment
of the virus by ultracentrifugation or of the viral DNA by ASFV-specific PCRs, and minimizes the
use of Sanger sequencing. Efficient DNA-se treatment, monitoring of sample preparation by qPCR,
and whole genome amplification are the key elements of the method. Through detailed description
of sequencing of the first Hungarian ASFV isolate (ASFV_HU_2018), we specify the sensitive steps
and supply key reference numbers to assist reproducibility and to facilitate the successful use of the
method for other ASFV researchers.
Keywords: African swine fever virus; ASFV; whole genome sequencing; whole genome amplification;
NGS; Illumina; Hungarian ASFV strain; DNAse treatment; whole genome amplification
1. Introduction
African swine fever virus (ASF) is a devastating disease affecting Sus scrofa; it infects both
domesticated pigs and wild boars. The ASF virus (ASFV) was most probably transmitted from its
natural hosts, warthogs (Phacochoerus spp.), bushpigs (Potamochoerus spp.) and soft ticks of the genus
Ornithodoros to domestic pigs (Sus scrofa domesticus) in southeast Africa [1,2]. The virus is endemic in
the Sub-Saharan region, where viral reservoir is maintained by a sylvatic cycle between the soft ticks
and its natural hosts [3,4]. In countries with temperate climate, mainly direct contact between domestic
pigs and wild boars, and indirect contact facilitated by human activity sustain the infectious cycle [4,5].
First transmission of ASFV to domestic pigs was reported in East Africa in 1921 [3]. The virus was
introduced into Europe in several successive waves; genotype I virus spread to the Southern Europe
in the 1950’s and 1960’s, while the well documented emergence of genotype II ASFV occurred in
Georgia in 2007 [6]. Since 2017 the virus has continuously spread westward in Eastern Europe, reaching
Hungary and Belgium, then in 2018 it arrived to China, and by now it became arguably the biggest
economic and animal health threat to the swine industry of the world [7,8].
ASFV is an enveloped virus with a large (170−190 kilo base pair) double stranded, covalently
closed, linear DNA genome, which contains around 200 open reading frames. The genome organization
Viruses 2019, 11, 1129; doi:10.3390/v11121129 www.mdpi.com/journal/viruses
Viruses 2019, 11, 1129 2 of 15
of the virus is reminiscent that of the poxviruses: it consists of a more conserved central area (approx.
125 kb) flanked by two variable regions (38-47 kb and 13–16 kb, respectively) at the ends of the
genome [6,9,10].
The ASFV has a high genetic and antigenic diversity. Determined by the p72 protein (B646L), so
far 24 genotypes have been identified, while based on hemadsorption inhibition at least 8 serotypes are
recognized [11,12]. All genotypes occur in Africa, from which genotype I of West African origin caused
outbreaks in the European, Caribbean, and South and Central American regions before 2007. However,
the pandemic that originated from Georgia was caused by the emergence of a genotype II virus of
East African origin [13]. Comparison of the complete sequences of the original Georgia 2007/1 genome
and the Polish ASFV/Pol/2015/Podlaskie genome isolated eight years later revealed only 95 nucleotide
differences scattered in the 190 000 bp genome, suggesting a relatively slow in vivo evolution of this
genotype II ASFV in pigs [14].
Vaccine development is hampered by the lack of detailed knowledge about viral virulence and
immunological factors influencing the outcome of infection of and immune response to ASFV. Currently
there are no available continuous cell lines supporting the replication of ASFV field isolates without
major genetic makeovers. Adaptation of ASFV to established cell lines usually leads to genome
destabilization and loss of ability to replicate in macrophages in vitro and in vivo. However, ASFV can
be isolated and replicated in primary macrophages without obvious genetic alterations [15,16].
So far, only 69 near complete genome sequences (including unverified ones and sequences from
patents) have been deposited into the GenBank (status 31.10.2019) [17] despite the obvious animal
health significance of the virus. Attempts to produce additional complete sequences of biologically
relevant ASFV strains are frequently thwarted by technical problems, such as difficulty in achieving
sequencing grade ASFV DNA and applying the most suitable next generation sequencing (NGS)
method for their production. To facilitate much needed epidemiological investigations, advance
research and vaccine development, it would be expedient to have a simple and reproducible method
for full genome sequencing of the ASFV.
In this paper we present a protocol that was successfully used to sequence the first Hungarian
isolate of ASFV and in our opinion fulfills the aforementioned criteria.
2. Materials and Methods
2.1. PAM Preparation and Culture
Porcine alveolar macrophages (PAMs) were prepared according to the OIE Manuals [18] and
were stored in RPMI-1640 medium containing 30% bovine serum and 10% DMSO at −72 ◦C. PAMs
were cultured in PAM culturing media (RPMI-1640 medium supplemented with 10% (v/v) fetal bovine
serum, 100 U/mL penicillin, 100 µg/mL streptomycin, and 2 mM L-glutamine (Sigma-Aldrich, Saint
Louis, MO, USA) at 37 ◦C and in 5% CO2.
2.2. Virus Isolation and Immunofluorescence Detection
Tissue homogenates of an ASFV-infected carcass were prepared with Tissue Lyser (QIAGEN,
Hilden, Germany) in PAM culturing medium sterile-filtered with 0.2 µm Acrodisc syringe filter (Pall
Corporation, NY, USA) and serially diluted in half-log steps. 2 × 104 PAM cells (100 µL) were plated in
96-well plates, incubated for 16 h at 37 ◦C, and infected with 10 µL of the diluted tissue homogenates.
After three days of incubation, the supernatant was removed and stored at −72 ◦C, while cells were
permeabilized by 1% Triton-X and fixed in 3% formaldehyde solution. Infected cells were visualized
by anti-ASFV polyclonal sera and Goat Anti-Swine IgG (H+L) CF488A (Biotium, Fremont, CA, USA)
secondary antibody. Positive cells were detected under an Axio Observer D1 inverted fluorescence
microscope (Carl Zeiss Ag. Oberkochen, Germany).
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2.3. Viral Stock Preparation
PAM cells (105 cells in 1ml PAM culturing media) were infected with 30µL high-titre ASFV-infected
PAM cell supernatant in several wells of a 24-well plate and incubated at 37 ◦C. At 72 h post infection
(hpi), the supernatant was removed, aliquoted, and stored at −72 ◦C.
2.4. DNAse Treatment
The media of ASFV-infected cells were collected at 72 hpi and centrifuged at 13 000 g for 3 min to
get rid of cellular debris. Subsequently, to 100 µL of the supernatant 100 µL DNase I solution containing
20 µL 10× FastDigest buffer (Thermo Fischer, Waltham, MA, USA), 40 mM MgCl2 and 1.5 µL of the
DNase I (50 U/µL) (Thermo Fischer Scientific, Waltham, MA, USA) was added. The samples were
incubated at 37 ◦C for 1 h, after which 10 µL 0.5 M EDTA was added to stop the reaction.
2.5. DNA Purification
Viral DNA was purified with the High Pure Viral Nucleic Acid Kit (Roche, Basel Switzerland)
following the manufacturer’s recommendations. In brief, 200 µL binding buffer and 50 µL proteinase K
were added to 200 µL sample, mixed, and incubated at 72 ◦C for 10 min. An additional 100 µL binding
buffer was added to the samples, mixed and transferred to the nucleic acid-binding membranes. After
centrifugation at 8000× g for 1 min, the membranes were washed first with 500 µL inhibitor removal
buffer and twice with 450 µL wash buffer. The DNA was eluted by 50 µL elution buffer.
2.6. Quantitative PCR
ASFV specific dual quantitative PCR (qPCR) was executed by Virotype ASFV PCR Kit (Qiagen,
Hilden, Germany) according to the manufacturer’s recommendation.
2.7. Aspecific DNA Amplification
The viral DNA was amplified using the REPLI-g Mini Kit (Qiagen, Hilden, Germany), following
the manufacturer’s protocol. First, 5 µL denaturing buffer was added to 5 µL viral DNA sample and
incubated at room temperature for 3 min. After that 10 µL neutralizing buffer and 30 µL master mix
(containing 29 µL REPLI-g Reaction Buffer and 1 µL REPLI-g Mini DNA polymerase) were mixed
with the denatured sample. The tubes were incubated at 30 ◦C for 16 h, then the polymerase was
inactivated by heating up to 65 ◦C for 3 min.
2.8. Amplified DNA Clean Up
REPLI-g samples were purified using the NucleoSpin Gel and PCR clean-up Kit (Macherey-Nagel
Düren, Germany). Briefly, 200 µL NTI buffer was added to 50 µL of the sample. After mixing,
the solution was loaded to the spin column and centrifuged at 11,000× g for 1 min. The column was
washed first with 500, then with 200 µL NT3 buffer. The remnant of the wash buffer was removed
by centrifugation at 11,000× g for 1 min. The DNA was then eluted in 20 µL elution buffer, and its
concentration was measured with NanoDrop 2000 (Thermo Fischer Scientific, Waltham, MA, USA).
2.9. IonTorrent Sequencing
A total of 100 ng of DNA was subjected to enzymatic fragmentation using the reagents supplied
in the NEBNext Fast DNA Fragmentation & Library Prep Set for Ion Torrent kit (New England BioLabs,
Hitchin, United Kingdom) according to the manufacturer’s instructions with slight modifications.
In brief, 8 µL of DNA was mixed with 1 µL of NEBNext DNA Fragmentation Reaction buffer, 0.5 µL
MgCl2 (using a 10 mM stock), and 0.75 µL NEBNext DNA Fragmentation Master Mix. The mixture
was incubated at 25 ◦C for 20 min, then at 70 ◦C for 10 min. The adaptor ligation was performed
using reagents from the same kit, whereas barcoded adaptors were retrieved from the Ion Xpress
Barcode Adapters (Thermo Fischer Scientific, Waltham, MA, USA). Reaction components were used at
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a reduced volume: 2 µL T4 DNA Ligase Buffer for Ion Torrent, 2 µL barcode adapter mixture, 0.5 µL Bst
DNA Polymerase and 2 µL T4 DNA Ligase were combined with the fragmentation reaction mixture
and nuclease-free water to obtain a final volume of 20 µL. Adapter ligation was performed at 25 ◦C for
15 min, terminated at 65 ◦C for 5 min. After cooling on ice slurry, 2.5 µL of Stop Buffer was added to
the mixture. The barcoded library DNA samples were purified using the Gel/PCR DNA fragments
extraction kit (Geneaid Biotech, Ltd., Taipei, Taiwan) according to the manufacturer’s instructions.
The eluted DNA libraries were then run on 2% E-Gel SizeSelect II Agarose (Invitrogen, Carlsbad, CA,
USA). Products between 300 and 350 bp were directly used in the PCR mixture of the NEBNext Fast
DNA Fragmentation & Library Prep Set for Ion Torrent kit (New England BioLabs, Hitchin, United
Kingdom) without further purification.
Library amplification was made in a total volume of 50 µL (the reaction mixture consisted of
15 µL sample, 7.5 µL H2O, 25 µL enzyme mix, and 2.5 µL primer), the heat profile included an initial
denaturation at 98 ◦C for 30 s, followed by 12 amplification cycles (98 ◦C for 10 s, 58 ◦C for 30 s, 72 ◦C
for 30 s) and terminated at 72 ◦C for 5 min. The products were purified using the Gel/PCR DNA
fragments extraction kit (Geneaid). The library DNA was eluted in nuclease-free water and quantified
fluorometrically on Qubit 2.0 equipment using the Qubit dsDNA BR assay kit (Invitrogen, Carlsbad,
CA, USA). Subsequently, the library DNA was diluted to 10 to 14 pM, then clonally amplified by
emulsion PCR. This step was carried out according to the manufacturer’s instructions using the Ion
PGM Hi-Q View OT2 Kit on an Ion OneTouch 2 instrument. Enrichment of the templated beads (on
an Ion OneTouch ES machine) and further steps for pre-sequencing setup were performed according
to the 200-bp protocol of the manufacturer. The sequencing protocol recommended for the Ion PGM
sequencing kit on a 316 chip was strictly followed.
2.10. Illumina Sequencing
Illumina® Nextera XT DNA Library Preparation Kit (Illumina, San Diego, CA, USA) and Nextera
XT Index Kit v2 Set A (Illumina, San Diego, CA, USA) were used to prepare Illumina specific libraries.
DNA samples were diluted to 0.2 ng/µL in nuclease-free water (Promega, Madison, WI, USA) in a
final volume of 2.5 µL. For the tagmentation reaction, 5 µL Tagment DNA (TD) buffer with 2.5 µL
AmpliconTagment Mix (ATM) were used. Next, the samples were incubated at 55 ◦C for 6 min, using
the GeneAmp PCR System 9700 (Applied Biosystems, Foster City, CA, USA). The samples were then
allowed to cool to 10 ◦C before the immediate addition of 2.5 µL of the Neutralize Tagment (NT) buffer.
Neutralization was performed for 5 min at room temperature. A total of 7.5 µL of the Nextera PCR
Master Mix (NPM) was combined with i5 and i7 index primers (2.5 µL of each primer per well) and
added to the tagmented DNA sample. The index primers were incorporated into library DNA via
12 PCR cycles (each cycle consisted of the following steps: 95 ◦C for 10 s, 55 ◦C for 30 s, followed by
72 ◦C for 30 s). Following the PCR cycles, the samples were held at 72 ◦C for 5 min and then at 10 ◦C.
The PCR products were purified using Gel/PCR DNA Fragments Extraction Kit (Geneaid Biotech
Ltd., Taipei, Taiwan). The concentration of the purified DNA samples was quantified with Qubit 2.0
equipment using Qubit dsDNA HS Assay Kit (Thermo Fischer Scientific, Waltham, MA, USA). Library
DNAs were pooled and denatured. Denatured library pool at a final concentration of 1.5 pM was
loaded onto a NextSeq 500/550 Mid Output flowcell and sequenced using an Illumina® NextSeq 500
sequencer (Illumina, San Diego, CA, USA).
2.11. Mapping and Assembly
Sequence reads obtained by NGS were trimmed by using Geneious Prime 2019.0.3 (Biomatters
Ltd., Auckland New Zealand). The reads were mapped against the pig genome (Sscrofa11.1,
GenBank assembly accession: GCF_000003025.6) to determine and eliminate host DNA contaminations.
The purified reads were assembled to the viral genome by mapping these to the sequence ASFV
Belgium 2018/1 [19] strains as reference. The sensitivity of mapping was set to medium with three
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iteration. The graphic representation of coverage and gene predictions were made using Geneious
Prime 2019.0.3.
2.12. Sanger Sequencing
Three regions were amplified using Primestar GXL kit with GC buffer (Takara Bio Inc., Japan),
in 25 µL final volume with 1 µL of purified ASFV DNA according to the manufacturer’s instructions.
The amplification was performed using the following PCR program: 98 ◦C 30 s, 30 × (98 ◦C 10 s, 60 ◦C
15 s, 68 ◦C 1 min), 68 ◦C 2 min. The primer pairs used for the amplification of the different fragments
are listed in Table 1. The same primers were used for Sanger sequencing by BaseClear B.V. (Leiden,
Netherlands). Sequences of the amplicons were well defined from both directions upstream of the
poly C/G on each fragment, while downstream of the C/G tracts sequence slippage was detected in
each case. The size of the poly C/G tracts and the actual sequence around them were determined by
comparing and analyzing the reads of the opposing strands.
Table 1. Primers used to amplify three poly C/G regions.
Regions Primers
14067–14379
>seqASF_14234-F
CTGAGATAGCCAAATCAAAATAC
>seqASF_14234-R
CGATTGTAAACTGTATAGTTAATCG
15551–15809
>seqASFV_15670-F
CAAAGCAGCCTGTATATGCAATACC
>seqASFV_15670-R
CAATCATTCTATTGTAAACTGTAGAG
19845–20072
>seqASFV_20022-F
TAGTACATCAATGTTGTAAGTTTG
>seqASFV_20022-R
CTATCTAAACGTGCTTCTATGAATTC
2.13. Phylogenetic Analyses
Two phylogenetic analyses were conducted: first, ASFV complete genomes were compared, then
genotype I and II strains were picked from this analysis together with an outgroup strain for new tree
inference. The transposed 5′ genomic end of strain Estonia 2014 (LS478113) [20] was trimmed from
the genome to ease aligning. For phylogenetic tree inference, multiple alignments were conducted
using MAFFT [21] with the legacy gap penalty, and phylogenetic calculations were performed using
RAxML-NG v0.9.0 [22] based on alignments edited in trimAl v1.3 [23]. Evolutionary model selection
was performed using ModelTest-NG v0.1.5 [24] and the generalized time reversible (GTR) model had
the highest probability combined with discrete Gamma rate categories (+G) and the proportion of
invariant sites (+I) [25]. The robustness of the trees was determined with a non-parametric bootstrap
calculation using 1000 repeats. Phylogenetic trees were visualized using MEGA 7 [26], bootstrap values
are given as percentages if they reached 75%.
3. Results and Discussion
ASFV_HU_2018 was isolated from homogenized organ samples of a wild boar carcass on PAM
cells. The isolated virus was assigned to be sequenced to determine its genetic makeup and to gain
molecular epidemiological data that might help identify its origin. However, following published
NGS-based general viral metagenome sequencing protocols we were unable to assemble the complete
ASFV genome sequence. The main reason of the failure was that viral sequences represented only a
minor fraction (<0.5%) of the total NGS reads [27]
Similar problems were reported at the sequencing of other ASFV isolates and different methodical
approaches were pursued to overcome the difficulties [28–32]. These include animal infections [33],
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the complicated purification of the virus from animal blood [14,33], the enrichment of the virus by
ultracentrifugation or that of the viral DNA by ASFV-specific PCR in the samples, and the excessive
use of Sanger sequencing [14,29,30].
The majority of the “ASFV sequencing papers” that made their virus/host genome read ratio
available reported very low percentage (0.5–1.0%) [27,34] of viral reads that resulted in low coverage
and consequently, the frequent use of specific PCR-Sanger sequencing (SPSS) to patch up ambiguous,
uncovered or poorly covered genome stretches. Regrettably, large-scale use of SPSS can substantially
increase the time and money spent to achieve the complete sequence of a near 200 Kbp virus.
Wen and coworkers [32], gave up altogether the random “shotgun” approach of NGS and applied
a whopping 86 overlapping specific PCRs (and sequenced the amplicons by NGS) to complete an
ASFV genome after having very low percentage viral reads in their samples. This extreme example
makes obvious that the full advantage of NGS for ASFV sequencing can only be exploited if a high
percentage of the sample DNA derives from the viral sequence.
Having considered the aforementioned facts, our goal was to develop a simple and reliable
NGS-based ASFV sequencing protocol, in which animal housing or ultracentrifugation are not
involved, ASFV-specific PCRs can be minimized and can be executed in most of veterinary BSL3
laboratories using standard equipment. To achieve this, we concentrated on enriching the ASFV
genome and decreasing the contaminating host genome in the input DNA samples using the simplest
tools available to us.
3.1. Maximizing Viral DNA Content
To maximize viral titer, ASFV was propagated in PAM cells, and the dynamics of infected cells was
monitored by immunofluorescence at 24, 48, and 72 hpi. The infection rate and attached cell number
at 24 and 48 hpi varied greatly (0.5–20% and 15–60%, respectively), even when the same cell and
virus lots were used in parallel infections. However, quasi independently of the 24 hpi infection rate
usually 90% of the cells lysed at 72 hpi and ~90% of the remaining attached cells proved to be infected
(Figure 1). These observations indicated that the supernatants of the infected cells had to be collected
at 72 hpi. They were centrifuged to get rid of contaminating cells and cellular debris and used for total
DNA extraction. For DNA quantification, the Virotype ASFV PCR Kit (Qiagen, Hilden, Germany)
was chosen as it allowed the simultaneous detection of the ASFV DNA and the contaminating swine
genome by dual PCR. Ct values (~22 and ~29 for ASFV and pig DNA, respectively) indicated high
molar ratio of the ASFV genome in the average samples. However, our ultimate goal was to get a high
sequence read ratio between the virus and the host and this can be only achieved by a high mass ratio
between the two genomes in the NGS input sample. Knowing the Ct values and size of the host and
the ASFV genomes allowed us to roughly calculate the mass ratio of the two genomes. For example,
assuming equally efficient amplifications and taking into consideration the size difference of the host
(2.5 × 109 bp of the haploid genome) and the ASFV (2 × 105 bp) genomes, at least ~13.6 cycle difference
(2.5 × 109/2 × 105 = 1.25 × 104 = 213.6) would be expected in a sample which contains equal mass of
viral and host DNA. However, this assessment certainly underestimates the Ct difference measured in
such a sample, as the kit is optimized to reduce the effectiveness of the host-specific PCR, to increase
the sensitivity of the viral PCR [35]. Nonetheless, following the rationale presented above, the mass
ratio of the viral and the contaminating host DNA can be calculated with the formula (2 × 105/2y)/(2.5
× 109/2z) × 100 where y and z are Ct values measured in the two channels of the dual PCR, respectively.
In our specific case (2 × 105/221.6)/(2.5 × 109/229.1) × 100 = ~1.44%. Thus, relatively high Ct numbers
(~29) measured in the second channel lagging behind with only 7–8 Ct values of the virus-specific
channel in the reality indicated very high swine genome contents (>98.56%).
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containing added MgCl2. After 1-h incubation with 75U DNAse-I, the reaction was stopped with 
EDTA and viral nucleic acid was purified. In most cases, minimal increase (Ct +1-2) was detected 
between the Ct values of untreated and DNAse-treated samples indicating that a substantial part (25–
50%) of viral DNA in the supernatant packed into DNAse-I resistant virions. The amount of host 
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Figure 1. The effect of African swine fever virus (ASFV) infection on primary macrophages at 72 h
p.i. Cells were mock infected (A) or infected (B) with MOI of 3 of ASFV. The nuclei of the cells were
visualized by Hoechst 33342 reagent (blue), infected cells (red) were detected by ASFV positive sera
and CF488 labelled anti-pig secondary antibodies. Pictures were colored by computer.
3.2. Minimizing Contaminating Host Genome DNA
DNAse treatment and ultracentrifugation are widely used to get rid of contaminating host DNA
from ASFV samples [14,29,30,34]. Since ul racentrifug s are expensive and far from being standard
appliances in veterinary BSL3 laboratories, we concentr t d on incr asing the effectiveness of the
DNAse treatmen and monitoring its result.
Bovine serum-supplemented culture medium with cell lysate content is a complex protein solution
with a potential to inhibit DNAse I activity through bivalent ation and DNA binding [36,37]. To ensure
effec ve DNAse I reatment, t e culture medium was diluted two-fold in a nuclease buffer containing
added MgCl2. Aft r 1-h incubation wi h 75U DNAse-I, the reaction was stopped with EDTA and viral
nucle c acid was purified. In most cases, minimal increase (Ct +1-2) was detected between the Ct
values of untreated and DNAse-treated samples indicating that a substantial part (25–50%) of viral
DNA in the supernatant pack d into DNAse-I resistant virions. The amoun of ho t DNA on the other
hand decreased markedly, how ver, the extent of reduction varied from sample to sample as indicated
by the broad range of increase in the Ct value (4 to >13) in the secon chan el (Figure 2). Thes
ob ervation i i t the complexity d unpredictable nature of th virus-containing cell lysate a d
highlight the importance of the qPCR monitoring for the selection of the appropriate samples.
The addition of EDTA to inactivate the DNAse before DNA purification als seemed to be crucial.
Omission of this step resulted in complete loss of the viral DNA in the following DNA purification step
(data not shown), which suggests that inactivation of high concentrations of DNAse I is not a rapid
process in the binding buffer of the applied purification kit (surprisingly, supplier does not indicate
EDTA content) [38].
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Figure 2. Host and viral content of differently treated ASFV samples. Quantitative dual PCR was
executed by Virotype ASFV PCR Kit. Ct values of individual and averaged samples represented by
colored circles and grey box respectively. Averages were calculated from numbers of samples indicated
on X axis. Gray circles indicate minimum and aximum values. Ct values higher than 40 (undetectable
host DNA) are represented by 41. Whole genome amplification (WGA) was executed by REPLI-g
Mini Kit.
3.3. Nonspecific Amplification of the Viral DNA
To increase the absolute amount of DNA for the following NGS sample preparation protocols,
whole genome amplification (WGA) was performed by using the REPLI-g Mini Kit. WGA was expected
to sustain the original high viral/host DNA ratio by randomly and evenly multiplying host and viral
DNA. Purified DNA samples with the highest viral content (viral Ct ~23, host Ct >40) were chosen for
the reaction. After the WGA reaction qPCR revealed a ~1000-fold increase in the viral DNA content in
the reaction tube (Ct ~23 vs. Ct ~14), while the host DNA remained undetectable (Figure 2). DNA from
the WGA reaction was p rified with the ucleoSpin Gel and PCR clean-up kit and the purification
resulted in 0.3–0.8 µg DNA/reaction that were used for Ill mina and Ion Torrent NGS.
3.4. NGS Sequencing of the ASFV Genome
In the last few years, Illumina and Ion Torrent systems became the most frequently used GS
platforms fo whole genome sequencing of microorgani ms. To find th most ffectiv solution for
ASFV sequencing [39], we comp red the two methods by running two ASFV samples on each platform.
Analysi of the sequence data rev led that he number of viral re ds exceeded the reads of
the contaminating nucleic acids in all four samples (Table 2). This finding verified that the DNAse I
treatment together with the applied onitoring procedure is in fact able to warrant that the majority of
the DNA in the ASFV samples originate from the viral genome.
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Table 2. Qualifying data for four sequenced samples.
Method Samples ofASFV_HUN_2018
Viral Reads of
the Total (%)
Number of
Viral Reads
Mean
Coverage Std. Dev.
Ion PGM System S43 90.4 179,325 197 129.1
Ion PGM System S41 87.7 152,865 158 106.5
NextSeq Illumina S1 50 6,835,057 2557 1624.9
NextSeq Illumina S20 77 7,115,377 2692 1897.6
Genomes were assembled by mapping the viral reads to the sequence of ASFV Belgium 2018/1 [19]
strains as reference by using the Geneious Prime 2019.0.3 program. Numerous (~131) undefined
nucleotides, mainly in the form of single and double nucleotide insertions/deletions (indels) were
found in homopolymer tracts of the assembled genome of the Ion Torrent platform-sequenced samples
(minimum coverage 35) compared to the reference sequence. The high number of ambiguous reads
made the usefulness of the Ion Torrent platform questionable for ASFV genome sequencing and it was
omitted from further investigations.
The number of undefined nucleotides were much less frequent in the Illumina platform output.
After processing the data of one sample (~7 million viral reads), they were restricted to the three
“longest” homopolymer regions (14224–14236 (13C), 15665–15680 (16C), 19991–20001 (11G)) containing
more than 10 C/G nucleotides. The sequence ambiguities of these regions could not even be resolved
by processing all viral reads of the two Illumina samples (around 14 million viral reads). Thus,
to determine the accurate sequence of the ASFV_HU_2018 (Accession number: MN715134), these three
regions had to be sequenced by the Sanger method. The use of these SPSS indeed allowed completing
the full sequence of the isolate.
Short of these three poly C/G tracts, the Illumina reads gave an even coverage for most of the
genome in both samples (Mean coverage: 2692.4 with Std Dev: 1897.6 and 2557 with Std Dev: 1624.9)
except for the terminal regions where viral reads were underrepresented.
Handling the data of only one channel (~1.8 million reads) still supplied very good coverage on
most of the genome and resulted in five short nucleotide stretches (spanning altogether ~440 nucleotides)
with unsatisfying coverage (<10) within the two terminal regions (1–3200 and 188,800–190601) that
impeded the determination of the exact sequence (Figure 3). Although processing the data of two
(3.6 million reads) or three (5.4 million reads) channels decreased the extension of the shortage of reads,
it still left nucleotides unsatisfyingly (<10) covered in these 5 regions (Figure 3). The lower coverage of
the termini most probably comes from the reduced amplification of these regions by the REPLI-g Mini
Kit. The termini of the virus are covalently closed and contain inverted repeats (ITR) that facilitate the
quick rehybridization of the template strands. Thus, the ITRs can impede the annealing of the random
primers to these regions that leads to below average amplification and the underrepresentation of
these regions in the sequence reads.
In any case, it seems that the generation of around 7 million reads and 3 SPSS are needed to
assemble the complete sequence of an ASFV isolate with our protocol if we want to minimize the
number of SPSS. The significant decrease of the NGS reads necessitate the increase of SPSS in the
terminal regions.
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. . alysis of the Sequence
parison of the ASFV_HU_2018 sequ nce to the ASFV Belgium 2018/1 sequ nce resulted in
ucleotide mismatches at 15 sites; the majority of these (9 sites) being mutations in non-coding
re i s. r i ately t e sa e er f differences (19 mismatches at 14 sites) was found between
the ASFV_HU_2018 and the China/2018/AnhuiXCGQ isolate [32] (Table 3). This relatively low number
of differences provide indirect evidence for the good quality of sequencing in the different labs.
Table 3. Nucleotide differences between ASFV_HU_2018 and two recent ASFV isolates.
Differences between ASFV Belgium 2018/1 and ASFV_HUN_2018
Type Mutation Position Localisation Description of Differences
Indel deletC 1384. non-coding region
Indel deletT 2956. non-coding region
Indel deletA 12570. ASFV G ACD 00190 CDS
The ASFV_HUN_2018 contains the “common version”
of gene. The adenine insertion is unique in the ASFV
Belgium 2018/1.
Indel delet4C 1 670. MGF 110-13L The length of this cytosine rich region is variable amongisolates.
Indel delet2G 17845. non-coding region
Indel delet3G 20001. ASFV G ACD 00350 CDS The length of this guanine rich region is variable amongisolates.
Indel deletG 21799. non-coding region
Point mutation T->C 26419. MGF 360-10L N->S, This nucleotide position is variable among theisolates.
Indel insT 27422. non-coding region
Indel insT 73257. non-coding region
Point mutation G->A 88348. C315R
V->I
The “common version” of gene contains the codon of
valine. The isoleucine is unique in the ASFV_HUN_2018.
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Indel insG 103310. non-coding region
Point mutation T->C 109659. B263R This synonym nucleotide change is uniquein the ASFV_HUN_2018.
Point mutation A->G 145065. D117L
L->P
The “common version” of gene contains codon of
proline. This amino acid change is unique
in the ASFV Belgium 2018/1.
Quasispecies W (A/T) 190462. non-coding region Coverage: 318Adenine 58%; Thymine 42%
Quasispecies S (C/G) 190470. non-coding region Coverage: 298Cytosine: 41%, Guanine 59%
Differences between China/2018/AnhuiXCGQ and ASFV_HUN_2018
Type Mutation Position Localisation Description of Differences
Indel insA 1063. non-coding region
Indel insC 1392. non-coding region
Indel ins2C 14235. MGF 110-14L The length of this cytosine rich region is variable amongisolates.
Indel ins4G 17631. non-coding region
Indel deletG 17845. non-coding region
Indel delet2G 20001. ASFV G ACD 00350 CDS The length of this guanine rich region is variable amongisolates.
Point mutation G->A 88348. C315R
V->I
The “common version” of gene contains the codon of
valine. This amino acide is unique in the
ASFV_HUN_2018.
Point mutation T->C 109659. B263R This synonym nucleotide change is unique in theASFV_HUN_2018.
Point mutation A->G 129413. O174L
S->P
This amino acide change is unique in the
China/2018/AnhuiXCGQ
Point mutation A->G 129517. O174L
F->S
This amino acide change is unique in the
China/2018/AnhuiXCGQ
Point mutation A->G 129542 O174L
S->P
This amino acide change is unique in the
China/2018/AnhuiXCGQ
Indel insA 190122. DP60R The length of this cytosine rich region is variable amongisolates.
Quasispecies W (A/T) 190462. non-coding region Coverage: 318Adenine 58%; Thymine 42%
Quasispecies S (C/G) 190470. non-coding region Coverage: 298Cytosine: 41%, Guanine 59%
It is appealing that the majority of the otherwise small differences are located in non-coding regions
(9 and 7 sites, respectively). Considering that around 85% of the ASFV genome codes proteins and
assuming random mutation distribution, the majority of the mutations should be localized in the coding
regions (unless there is no purifying selection). This may suggest such a selection pressure on the viral
proteins that sustains not only their protein but also their nucleotide sequences. Phylogenetic analysis of
the ASFV complete genomes also support high genetic stability of the genotype II viruses. Interestingly,
it reveals considerably less evolutionary distance among genotype II viruses than genotype I viruses
(Figure 4). For example, the two most divergent genotype I viruses (Mkuzi 1979 [AY261362] and
BA71V [U18466]) show ~90% nucleic acid identity (without the large deletions in BA71V) while the
two most different genotype II ASFVs (2008/1 [MH910495] and Estonia 2014 [LS478113]) are almost
99.9% identical. This raises the question of whether genotype II viruses evolve at a lower speed in pigs
than type I viruses do. However, the different evolutionary time of the two genotypes in pigs and the
improving reliability of the sequencing technology since the emergence of ASFV makes the question
difficult to answer and it requires further research.
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numbers and t eir strain names. Genotypes I nd II are marked. (A). Phylogenetic analysis of different
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ASFV strains. The tree was rooted usi g strain Warthog as out roup. (C). The subtree of g notype II
strains shown s parately from the phylogenetic analysis of genotype I and II ASFV strains.
4. Conclusions
We developed an ASFV sequencing protocol that gives a simple and effective solution to the
common problem of viral DNA shortage and host DNA contamination in ASFV samples. Proper
application of the nuclease treatment, whole genome amplification by random PCR, and most
importantly, constant monitoring and evaluation of the effectiveness of different phases of sample
preparation allowed us to take full advantage of NGS for ASFV genome sequencing. Via sequencing of
the first Hungarian ASFV isolate, we highlighted sensitive steps and supplied key reference numbers
to assist reproducibility and to facilitate the successful use of this protocol for other ASFV researchers
(Figure 5).
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